[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:her2-positive-breast-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":48,"states":52},"HER2-Positive Breast Carcinoma",6,4,[8,16,22,28,34,42],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04348747","Dendritic Cell Vaccines Against Her2\u002FHer3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer",[12],"Phase 2","RECRUITING","2026-08-26T02:15:14.574786Z","2026-07-05T05:32:16.794666Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05795101","TRUDI: TDXD+Durva in HER2+\u002FLow IBC",[12],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:28.656877Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05115474","Study of Screening Brain MRIs in Stage IV Breast Cancer",[],"2026-08-26T02:19:04.543908Z","2026-05-13T02:55:06.292477Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT05396612","Role of the Immune Environment in Response to Therapy in Breast Cancer",[],"2026-08-26T02:16:22.235886Z","2026-05-13T02:55:06.349680Z",{"nct_id":35,"title":36,"phases":37,"status":39,"updated_at":40,"content_modified":41},"NCT07217990","Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer",[38],"Phase 1\u002FPhase 2","NOT_YET_RECRUITING","2026-08-26T02:19:24.527214Z","2026-05-05T02:43:27.065180Z",{"nct_id":43,"title":44,"phases":45,"status":39,"updated_at":46,"content_modified":47},"NCT07619534","Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases",[],"2026-08-26T02:15:10.362237Z","2026-06-04T01:30:07.905594Z",[49],{"biomarker":50,"count":6,"slug":51},"ERBB2 Gene","erbb2-gene",[]]